Additionally, TMAO activates the NLRP3 inflammasome, triggering the release of pro-inflammatory cytokines, exacerbating endothelial dysfunction, and impairing NO-mediated vasodilation [39]. The gene discussed is NLRP3; the disease is endothelial dysfunction.